Registration of securities issued in business combination transactions

Statements of Cash Flows (Mymd Pharmaceuticals Inc.)

v3.20.4
Statements of Cash Flows (Mymd Pharmaceuticals Inc.) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from Operating activities    
Net loss $ (17,580,609) $ (3,888,249)
Adjustments to reconcile net loss to net cash flows from operating activities    
Share based compensation
Increase (decrease) in cash from changes in:    
Accounts payable 733,530 (443,735)
Net cash used in operating activities (11,924,941) (3,074,283)
Cash flows from Financing activities    
Proceeds from sale of common stock 29,184,244 2,147,778
Net cash provided by financing activities 38,667,827 6,965,693
Net change in cash 17,985,417 (49,217)
Cash and cash equivalents and restricted cash at beginning of year 632,538 681,755
Cash and cash equivalents and restricted cash at end of year 18,617,955 632,538
Mymd Pharmaceuticals Inc. [Member]    
Cash flows from Operating activities    
Net loss (8,930,465) (9,638,916)
Adjustments to reconcile net loss to net cash flows from operating activities    
Share based compensation 855,000 3,577,550
Option modification expense 2,009,145
Amortization of debt issuance costs 1,191,859 235,552
Non-cash amortization expense 18,334 18,333
Increase (decrease) in cash from changes in:    
Prepaid expenses and other current assets 16,254 (12,180)
Accounts payable 146,443 489,235
Accrued interest, related party 165,040 10,639
Net cash used in operating activities (4,528,390) (5,319,787)
Cash flows from Financing activities    
Proceeds from sale of common stock 1,980,000 2,959,000
Proceeds from Paycheck Protection Program loan 54,000
Proceeds from line of credit, related party 1,680,241 1,920,619
Payments on line of credit, related party (408,741)
Proceeds from loan payable, related party 1,200,000
Advances from related party 24,600 11,903
Net cash provided by financing activities 4,530,100 4,891,522
Net change in cash 1,710 (428,265)
Cash and cash equivalents and restricted cash at beginning of year 132,023 560,288
Cash and cash equivalents and restricted cash at end of year 133,733 132,023
Supplemental disclosure of cash flow information    
Issuance of stock options for debt issuance costs 839,457 1,165,816
Modification of options recorded as increase in debt discount $ 880,020